Autor/es reacciones
Ángel Carracedo Álvarez
Professor Emeritus in the Department of Forensic Sciences, Pathological Anatomy, Gynaecology and Obstetrics, and Paediatrics at the University of Santiago de Compostela, and head of the Genomic Medicine group
The fact that around 25 per cent of participants in the All of Us cohort have actionable pharmacogenetic variants for a particular drug is significant and supports the need for cost-effectiveness studies to determine whether pharmacogenetic screening strategies and alerts in medical records might prove useful in the future.
EN